138304-74-2

Basic information

• Product Name: Piperazine, 1-[2-(4-methylphenoxy)ethyl]-
• CAS NO: 138304-74-2
• Molecular Formula: C13H20N2O
• Molecular Weight: 220.315
• Mol File: 138304-74-2.mol

Chemical Properties

• CAS DataBase Reference: Piperazine, 1-[2-(4-methylphenoxy)ethyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Piperazine, 1-[2-(4-methylphenoxy)ethyl]-(138304-74-2)
• EPA Substance Registry System: Piperazine, 1-[2-(4-methylphenoxy)ethyl]-(138304-74-2)

Safety Data

• Hazardous Substances Data: 138304-74-2(Hazardous Substances Data)

Upstream product

• 106-44-5 p-cresol 

Downstream Products

• 1329494-32-7 phenyl (4-(2-(4-methoxyphenoxy)ethyl)piperazin-1-yl)methanone 
• 1326982-99-3 thiophen-2-yl(4-(2-(p-tolyloxy)ethyl)piperazin-1-yl)methanone 
• 178105-48-1 2-Amino-4-(2,5-dichlorophenyl)-6-[4-[2-(4-methylphenoxy)ethyl]piperazin-1-yl]-1,3,5-triazine 

Relevant articles and documents

Discovery of 1-aryloxyethyl piperazine derivatives as Kv1.5 potassium channel inhibitors (part I)

Kv1.5 potassium channel is an efficacious and safe therapeutic target for the treatment of atrial fibrillation (AF), the most common arrhythmia that threatens human. Herein, by modifying the hit compound 7k from an in-house database, 48 derivatives were synthesized for the assay of their Kv1.5 inhibitory effects by whole cell patch clamp technique. Six compounds which showed better potency than the positive compound dronedarone were selected for the next evaluation of their drug-like properties. Compound 8 exhibited balanced solubility and permeability. It also showed acceptable pharmacodynamics profile with very low acute toxicity. Taking all these data into account, compound 8 can serve as a promising lead for the development of novel therapeutic agent for the treatment of AF.

Benzo[d]isothiazole-3-(2H)-one derivative, preparation method and application thereof

The invention relates to a benzo[d]isothiazole-3-(2H)-one derivative, a preparation method and application of the benzo[d]isothiazole-3-(2H)-one derivative. The compound is a free alkali or salt of acompound with a structure shown in a general formula (I). The salt is one of hydrochloride, hydrobromide, sulfate, trifluoroacetate, tartrate, lactate or mesylate; R1 independently represents "-CH2-CO-" or "-CH2-CH2-"; R2 independently represents "-CH2-CH2-O-" or "-CO-CH=CH-"; R3 independently represents hydrogen, halogens, a hydrocarbon group, a halogen-substituted hydrocarbon group, a nitro group, an amino group, a nitrile group, a hydroxyl group, an alkoxy group, an aryloxy group, a heterocycloalkoxy group, an aryl group, a substituted heterocyclic ring or a substituted aryl group. The invention also provides an application of the benzo[d]isothiazole-3-(2H)-one derivative in preparation of ischemic stroke treatment medicines.